Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin
HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company...
Brain
Nexalin Technology Announces Issuance of U.S. Patent Covering HALO™ Clarity Device Featuring DIFS™ Technology
HOUSTON, TX, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader...
Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients
Late-breaking clinical data presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis Across non-active...
Helius Announces FDA 510(k) Submission for PoNS® Device Label Expansion in Stroke
Seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under its Breakthrough Device DesignationNEWTOWN,...
Algernon Announces CAD $4 Million Non-Dilutive Financing to Open Four Brain-Specific PET Scan Clinics in the U.S. for Early Stage Alzheimer’s Detection
VANCOUVER, British Columbia, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB:...
Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine
Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine Detailed results from completed...
Breakthrough San Diego Clinic Uses Cutting-Edge NUCCA Technique to Reverse Chronic Pain and Restore Quality of Life – Without Drugs or Surgery
San Diego-based Origin Modern Health & Wellness uses powerful, gentle root cause care, reconnecting individuals to their body's potential. SAN...
15th Annual Nikon Small World in Motion Competition Winner Magnifies Self-Pollination Process in a Common Wildflower
Time-lapse video of a thymeleaf speedwell reveals the reproductive strategy select plants may adopt when pollinators are scarce MELVILLE, N.Y., Sept....
FYR Closes $8 Million Financing to Advance Blood-Based Biomarkers Across Oncology and Neuroscience
The Sontag Innovation Fund and the Yuvaan Tiwari Foundation join Two Bear Capital to support FYR's growing oncology portfolio and...
NUCALM IGNITES THE POWER OF VOICE WITH CELEBRATED COACH ROGER LOVE
Harnessing Neuroscience and Voice Mastery to Transform How Humans Communicate and Connect LOS ANGELES, Sept. 24, 2025 /PRNewswire/ -- NuCalm®,...
A Historic Leap Toward Curing Heart Disease: New Study Shows Cavadex Dramatically Reverses Symptoms and Restores Quality of Life in High-Risk Patients
Groundbreaking Observational Study Reveals 88% of Participants Experienced Significant Health Improvements, Offering Unprecedented Hope in the Fight Against the World's...
A Historic Leap Toward Curing Heart Disease: New Study Shows Cavadex Dramatically Reverses Symptoms and Restores Quality of Life in High-Risk Patients
Groundbreaking Observational Study Reveals 88% of Participants Experienced Significant Health Improvements, Offering Unprecedented Hope in the Fight Against the World's...
Jaguar Health Submits Orphan Drug Designation Application to FDA for Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Patients with Breast Cancer with Metastasis Identified by FDA as a Distinct Condition
Potential treatment for patients with breast cancer with metastasis to the brain with crofelemer would augment the significant responder analysis...
EGI Launches Next-Generation HD-EEG Platform to Advance Understanding of Brain Function and Stimulation
Innovator of HD-EEG releases world’s most advanced EEG brain monitoring technology for neuroscience research EGI GES 500 Next-Generation HD-EEG Platform...
LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia
TOKYO and CAMBRIDGE, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and...
uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease
~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by...
New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies
ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis...
Roche presents new data for OCREVUS and fenebrutinib across broad patient populations at ECTRIMS 2025
OCREVUS subcutaneous maintains consistent benefit-risk profile after two years New late-breaking data confirms OCREVUS significantly reduces disability progression in adults...
Synendos Therapeutics Reports Positive and Highly Promising Topline Results from Phase 1 Trials, Paving the Way for Phase 2 in Mental Health
The studies established the lead asset to be well tolerated in healthy volunteers at all doses with a good safety...
Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients
WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical...